Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Auxens was a French medical technology company specializing in the development of cold atmospheric plasma (CAP) devices for wound healing and dermatology. Spun off from the GREMI laboratory, a collaboration between CNRS and the University of Orléans, the company focused on translating plasma physics into clinical applications. Their flagship product, Exo-Plasma, was a portable device designed to treat chronic wounds such as diabetic foot ulcers and pressure sores by applying ionized gas at room temperature. This technology provided a dual benefit of reducing bacterial load and stimulating tissue regeneration without damaging healthy skin. Despite achieving clinical milestones and developing a robust intellectual property portfolio, the company ceased its operations and was liquidated in 2022.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Auxens Médical.